The role of interleukin-24 in atopic dermatitis

Atopic dermatitis (AD) is characterized by skin barrier disruption, type 2 immune dysregulation, chronic pruritus, and abnormal colonization by Staphylococcus aureus (S. aureus). Tapinarof, an aryl hydrocarbon receptor modulator, has been demonstrated to attenuate the development of AD in clinical s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yen Hai Vu, Masutaka Furue, Gaku Tsuji
Formato:	article
Lenguaje:	EN
Publicado:	Open Exploration Publishing Inc. 2021
Materias:	atopic dermatitis interleukin-24 aryl hydrocarbon receptor tapinarof janus kinase inhibitor dupilumab Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/856e2ee9c914464eabc7d770cfa8b188
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:856e2ee9c914464eabc7d770cfa8b188
record_format	dspace
spelling	oai:doaj.org-article:856e2ee9c914464eabc7d770cfa8b1882021-11-24T01:35:18ZThe role of interleukin-24 in atopic dermatitis10.37349/ei.2021.000022768-6655https://doaj.org/article/856e2ee9c914464eabc7d770cfa8b1882021-04-01T00:00:00Zhttps://www.explorationpub.com/Journals/ei/Article/10032https://doaj.org/toc/2768-6655Atopic dermatitis (AD) is characterized by skin barrier disruption, type 2 immune dysregulation, chronic pruritus, and abnormal colonization by Staphylococcus aureus (S. aureus). Tapinarof, an aryl hydrocarbon receptor modulator, has been demonstrated to attenuate the development of AD in clinical studies. Recently, we found that tapinarof upregulated the expression of filaggrin and loricrin, which are essential proteins in skin barrier functions. Paradoxically, tapinarof induced interleukin (IL)-24 secretion by normal human keratinocytes. IL-24 is produced by T helper 2 lymphocytes and keratinocytes following stimulation by type 2 cytokines, and IL-24 is upregulated in the skin of patients with AD. Furthermore, IL-24 contributes to skin barrier disruption and hyperplasia in AD, and it may exacerbate skin inflammatory responses, itch, and S. aureus infection. In this review, we summarized the current findings regarding the detrimental role of IL-24 in AD, thereby suggesting that co-treatment of tapinarof with therapeutics that block IL-24 signaling may represent a promising strategy for managing AD.Yen Hai VuMasutaka FurueGaku TsujiOpen Exploration Publishing Inc.articleatopic dermatitisinterleukin-24aryl hydrocarbon receptortapinarofjanus kinase inhibitordupilumabImmunologic diseases. AllergyRC581-607ENExploration of Immunology, Vol 1, Iss 1, Pp 4-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopic dermatitis interleukin-24 aryl hydrocarbon receptor tapinarof janus kinase inhibitor dupilumab Immunologic diseases. Allergy RC581-607
spellingShingle	atopic dermatitis interleukin-24 aryl hydrocarbon receptor tapinarof janus kinase inhibitor dupilumab Immunologic diseases. Allergy RC581-607 Yen Hai Vu Masutaka Furue Gaku Tsuji The role of interleukin-24 in atopic dermatitis
description	Atopic dermatitis (AD) is characterized by skin barrier disruption, type 2 immune dysregulation, chronic pruritus, and abnormal colonization by Staphylococcus aureus (S. aureus). Tapinarof, an aryl hydrocarbon receptor modulator, has been demonstrated to attenuate the development of AD in clinical studies. Recently, we found that tapinarof upregulated the expression of filaggrin and loricrin, which are essential proteins in skin barrier functions. Paradoxically, tapinarof induced interleukin (IL)-24 secretion by normal human keratinocytes. IL-24 is produced by T helper 2 lymphocytes and keratinocytes following stimulation by type 2 cytokines, and IL-24 is upregulated in the skin of patients with AD. Furthermore, IL-24 contributes to skin barrier disruption and hyperplasia in AD, and it may exacerbate skin inflammatory responses, itch, and S. aureus infection. In this review, we summarized the current findings regarding the detrimental role of IL-24 in AD, thereby suggesting that co-treatment of tapinarof with therapeutics that block IL-24 signaling may represent a promising strategy for managing AD.
format	article
author	Yen Hai Vu Masutaka Furue Gaku Tsuji
author_facet	Yen Hai Vu Masutaka Furue Gaku Tsuji
author_sort	Yen Hai Vu
title	The role of interleukin-24 in atopic dermatitis
title_short	The role of interleukin-24 in atopic dermatitis
title_full	The role of interleukin-24 in atopic dermatitis
title_fullStr	The role of interleukin-24 in atopic dermatitis
title_full_unstemmed	The role of interleukin-24 in atopic dermatitis
title_sort	role of interleukin-24 in atopic dermatitis
publisher	Open Exploration Publishing Inc.
publishDate	2021
url	https://doaj.org/article/856e2ee9c914464eabc7d770cfa8b188
work_keys_str_mv	AT yenhaivu theroleofinterleukin24inatopicdermatitis AT masutakafurue theroleofinterleukin24inatopicdermatitis AT gakutsuji theroleofinterleukin24inatopicdermatitis AT yenhaivu roleofinterleukin24inatopicdermatitis AT masutakafurue roleofinterleukin24inatopicdermatitis AT gakutsuji roleofinterleukin24inatopicdermatitis
_version_	1718416044713836544

The role of interleukin-24 in atopic dermatitis

Ejemplares similares